Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01852019 · ClinicalTrials.gov registry record · Phase 2
Cangrelor Prasugrel Transition Study
A Phase 2 study, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01852019 is a Phase 2 study that has completed, run by The Medicines Company. The registered enrollment target is 12 participants.
The verdict
NCT01852019, a Phase 2 study, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
To demonstrate that patients treated with cangrelor can be directly switched to oral prasugrel and that patients treated with prasugrel can be switched to cangrelor without a significant decrease in the extent of inhibition of platelet aggregation.
Interventions
- DRUG Prasugrel
- DRUG Cangrelor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01852019
The ClinicalTrials.gov registry entry for NCT01852019 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prasugrel is the first listed.
NCT01852019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01852019 about?
NCT01852019 is a clinical study titled "Cangrelor Prasugrel Transition Study". To demonstrate that patients treated with cangrelor can be directly switched to oral prasugrel and that patients treated with prasugrel can be switched to cangrelor without a significant decrease in the extent of inhibition of platelet aggregation.
What is the current status of trial NCT01852019?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2013-06. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01852019?
The interventions under investigation include: Prasugrel (DRUG), Cangrelor (DRUG).
Who is sponsoring clinical trial NCT01852019?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.